EMA Authorised: Revestive (teduglutide) — Takeda Pharmaceuticals International AG Ireland

View source ↗

Summary

The European Medicines Agency authorised Revestive (teduglutide) for malabsorption syndromes. The decision date was 22 May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malabsorption Syndromes
• Short Bowel Syndrome

Drugs mentioned

• Revestive (teduglutide)

Snippet

Status: Authorised. Therapeutic area: Malabsorption Syndromes. MAH: Takeda Pharmaceuticals International AG Ireland. Decision date: 22/05/2025